Fiduciary Trust Co Sells 94 Shares of STERIS plc (NYSE:STE)

Fiduciary Trust Co lessened its holdings in shares of STERIS plc (NYSE:STE) by 2.9% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,176 shares of the medical equipment provider’s stock after selling 94 shares during the period. Fiduciary Trust Co’s holdings in STERIS were worth $770,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. Ashton Thomas Securities LLC bought a new position in STERIS in the third quarter valued at approximately $25,000. Central Pacific Bank Trust Division acquired a new stake in shares of STERIS during the third quarter worth $28,000. Versant Capital Management Inc lifted its position in STERIS by 2,262.5% in the 2nd quarter. Versant Capital Management Inc now owns 189 shares of the medical equipment provider’s stock valued at $41,000 after acquiring an additional 181 shares in the last quarter. Brown Brothers Harriman & Co. boosted its stake in STERIS by 154.7% in the 2nd quarter. Brown Brothers Harriman & Co. now owns 191 shares of the medical equipment provider’s stock worth $42,000 after purchasing an additional 116 shares during the period. Finally, Isthmus Partners LLC bought a new position in STERIS during the 2nd quarter worth about $44,000. 94.69% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other STERIS news, CFO Michael J. Tokich sold 23,332 shares of STERIS stock in a transaction on Tuesday, September 10th. The shares were sold at an average price of $247.00, for a total transaction of $5,763,004.00. Following the completion of the transaction, the chief financial officer now directly owns 42,930 shares of the company’s stock, valued at $10,603,710. The trade was a 35.21 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, SVP Cary L. Majors sold 1,682 shares of the stock in a transaction dated Monday, November 25th. The shares were sold at an average price of $217.32, for a total transaction of $365,532.24. Following the completion of the transaction, the senior vice president now directly owns 11,372 shares in the company, valued at $2,471,363.04. The trade was a 12.88 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.14% of the stock is owned by insiders.

STERIS Price Performance

NYSE:STE opened at $219.06 on Friday. The stock has a market capitalization of $21.62 billion, a PE ratio of 50.01 and a beta of 0.85. STERIS plc has a 1-year low of $195.47 and a 1-year high of $248.24. The firm has a fifty day simple moving average of $225.01 and a 200 day simple moving average of $228.28. The company has a current ratio of 2.41, a quick ratio of 1.55 and a debt-to-equity ratio of 0.33.

STERIS (NYSE:STE) last announced its quarterly earnings data on Wednesday, November 6th. The medical equipment provider reported $2.14 EPS for the quarter, beating analysts’ consensus estimates of $2.12 by $0.02. STERIS had a net margin of 8.02% and a return on equity of 13.78%. The company had revenue of $1.33 billion during the quarter, compared to the consensus estimate of $1.33 billion. During the same quarter last year, the firm posted $2.03 EPS. The company’s quarterly revenue was up 7.3% on a year-over-year basis. On average, research analysts expect that STERIS plc will post 9.15 EPS for the current fiscal year.

STERIS Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, December 19th. Stockholders of record on Tuesday, November 19th will be paid a dividend of $0.57 per share. The ex-dividend date is Tuesday, November 19th. This represents a $2.28 annualized dividend and a dividend yield of 1.04%. STERIS’s dividend payout ratio is currently 52.05%.

Analyst Upgrades and Downgrades

STE has been the subject of several recent research reports. StockNews.com cut STERIS from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, October 29th. Piper Sandler raised STERIS from a “neutral” rating to an “overweight” rating and upped their price target for the stock from $230.00 to $260.00 in a research report on Thursday, October 24th. JMP Securities reiterated a “market outperform” rating and issued a $265.00 price objective on shares of STERIS in a report on Monday, November 18th. Stephens restated an “overweight” rating and set a $260.00 target price on shares of STERIS in a report on Thursday, November 7th. Finally, KeyCorp lifted their price target on shares of STERIS from $255.00 to $265.00 and gave the company an “overweight” rating in a research note on Tuesday, September 3rd. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat.com, STERIS presently has an average rating of “Moderate Buy” and an average target price of $253.00.

About STERIS

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.